Press Releases April 8, 2026 08:00 PM

707 Cayman Holdings to Effect Share Consolidation on April 13, 2026

707 Cayman Holdings to consolidate shares 20-for-1 to regain Nasdaq compliance

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
JEM

707 Cayman Holdings Limited announced a 20-for-1 share consolidation effective April 13, 2026, to comply with Nasdaq Marketplace Rule 5550(a)(2) and maintain its Nasdaq listing. Post-consolidation, the company will have fewer outstanding shares trading under the same ticker symbol JEM with a new CUSIP.

707 Cayman Holdings to Effect Share Consolidation on April 13, 2026
JEM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • 707 Cayman Holdings will consolidate its shares on a 20-for-1 basis to regain compliance with Nasdaq listing requirements.
  • The share consolidation will reduce the outstanding shares from approximately 28.2 million to 1.4 million for Class A shares.
  • The shares will continue trading on Nasdaq under the symbol JEM with a new CUSIP starting April 13, 2026.

HONG KONG, April 09, 2026 (GLOBE NEWSWIRE) -- 707 Cayman Holdings Limited (“707” or the “Company”) (Nasdaq: JEM), a Hong Kong-based company that sells quality apparel products and provides supply chain management total solutions, today announced that the Company’s board of directors approved on March 4, 2026 that the authorized, issued, and outstanding shares of the Company be consolidated on a 20 for 1 ratio with the marketplace effective date of April 13, 2026.

The objective of the share consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq.

Beginning with the opening of trading on April 13, 2026, the Company’s Class A ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol “JEM” but under a new CUSIP number, G8071C111.

As a result of the share consolidation, each 20 ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. The number of issued and outstanding ordinary shares of the Company will be correspondingly reduced from 28,219,360 Class A Ordinary Shares to approximately 1,410,968 Class A Ordinary Shares and 7,806,000 Class B Ordinary Shares to 390,300 Class B Ordinary Shares, subject to adjustment for rounding. No fractional shares will be issued to any shareholders in connection with the share consolidation, and each shareholder will be entitled to receive one share of the Company in lieu of the fractional share of that class that would have resulted from the share consolidation.

About 707 Cayman Holdings Limited

707 Cayman Holdings Limited is a Hong Kong-based company that sells quality apparel products and provides supply chain management total solutions to our customers spanning from Western Europe, North America to the Middle East. Our customers include mid-size brand owners and apparel companies that have comprehensive operations with private labels that are sold worldwide.

707 Cayman Holdings Limited Contact:

HBK Strategy Limited
[email protected]
+852 2156 0223


Risks

  • The need for consolidation indicates prior non-compliance with Nasdaq listing rules, which may reflect underlying performance or market perception risks.
  • Share consolidation can lead to reduced liquidity in the stock due to fewer outstanding shares, potentially impacting trading volume.
  • There is uncertainty whether this measure alone will sustain long-term compliance and investor confidence.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026